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ABSTRACT
Triple negative breast cancers are an aggressive subtype of breast cancer, 
characterized by the lack of estrogen receptor, progesterone receptor and Her2 
expression. Triple negative breast cancers are non-responsive to conventional anti-
hormonal and Her2 targeted therapies, making it necessary to identify new molecular 
targets for therapy. The chemokine CCL2 is overexpressed in invasive breast cancers, 
and regulates breast cancer progression through multiple mechanisms. With few 
approaches to target CCL2 activity, its value as a therapeutic target is unclear. In 
these studies, we developed a novel gene silencing approach that involves complexing 
siRNAs to TAT cell penetrating peptides (Ca-TAT) through non-covalent calcium 
cross-linking. Ca-TAT/siRNA complexes penetrated 3D collagen cultures of breast 
cancer cells and inhibited CCL2 expression more effectively than conventional 
antibody neutralization. Ca-TAT/siRNA complexes targeting CCL2 were delivered to 
mice bearing MDA-MB-231 breast tumor xenografts. In vivo CCL2 gene silencing 
inhibited primary tumor growth and metastasis, associated with a reduction in cancer 
stem cell renewal and recruitment of M2 macrophages. These studies are the first 
to demonstrate that targeting CCL2 expression in vivo may be a viable therapeutic 
approach to treating triple negative breast cancer.
INTRODUCTION
The molecular heterogeneity of breast cancers is 
well recognized, with at least five different subtypes 
identified through molecular profiling. Basal-like breast 
cancers comprise up to 15% of all of breast cancer cases 
diagnosed in the US and Canada. However, patients 
diagnosed with basal-like breast cancers exhibit the 
shortest time for overall survival and recurrence free 
survival [1-3]. 75% of basal–like breast cancers are triple 
negative (TNBC); i.e, they lack expression of Her2, 
progesterone receptor and estrogen receptors. TNBCs are 
non-responsive to endocrine and targeted Her2 therapies 
[4-6]. In order to treat TNBC more effectively, it is 
necessary to identify new molecular targets tailored to this 
disease subtype.
CCL2 (MCP-1) represents a promising molecular 
target for therapeutic intervention. CCL2 belongs to 
a family of small soluble molecules (8kDa) known as 
chemokines, and bind to G protein coupled receptors to 
regulate macrophage recruitment during wound healing, 
inflammation and infection [7-14]. Chronic overexpression 
of CCL2 contributes to inflammatory diseases including 
rheumatoid arthritis, fibrosis and macular degeneration 
[15, 16]. Overexpression of CCL2 in the tumor epithelium 
correlates with tumor grade and poor patient prognosis in 
various tumor types including: gliomas, prostate cancers, 
ovarian cancers and breast cancers [17, 18]. In primary 
prostate and mammary tumors, CCL2 overexpression 
correlates with recruitment of M2 polarized macrophages, 
a subpopulation of macrophages that facilitate tumor 
progression through secretion of growth and survival 
factors [19, 20]. In functional studies, CCL2 antibody 
neutralization in 4T1 or MDA-MB-231 breast tumor 
xenografts inhibited tumor growth and metastasis, while 
decreasing the levels of macrophages in the primary 
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tumors, indicating that CCL2 promotes progression 
of TNBC [21-23] through macrophage dependent 
mechanisms. Recent studies demonstrate that CCL2 
also signal to breast cancer cells to regulate survival and 
invasion [24]. These studies indicate that CCL2 regulates 
multiple mechanisms of breast cancer progression, 
demonstrating potential value as a therapeutic target.
Currently, the value of CCL2 as a therapeutic target 
is controversial. CCL2 neutralizing antibodies effectively 
blocked rheumatoid arthritis in mouse models, yet failed 
in clinical trials. Patients treated with CCL2 neutralizing 
antibodies showed accumulating levels of protein [25]. 
In breast tumor bearing mice, continuous treatment 
with CCL2 neutralizing antibodies inhibited mammary 
tumor progression. However, termination of treatment 
led to increased metastasis, which was associated with 
increased tumor angiogenesis [26]. These studies indicate 
that either CCL2 is not an effective therapeutic target or 
that neutralizing antibodies are a suboptimal method for 
blocking CCL2 activity. To more clearly evaluate these 
possibilities, we developed a novel approach to target 
CCL2 through gene silencing.
Gene silencing through small interfering RNAs 
(siRNAs) could selectively inactivate expression and 
activity of critical oncogenes, but would require a 
carrier to efficiently and specifically penetrate tumor 
cells and tissues [27-29]. The HIV-1 derived trans-
activating transcriptor peptide (TAT49-57: RKKRRQRRR) 
exhibits unusual properties by efficiently penetrating cell 
membranes, independent of temperature or cell surface 
receptor expression but do not stably complex with 
siRNAs or DNA [30-32]. Recent discoveries made by our 
research group showed that calcium ions strengthened the 
interactions between TAT peptides to siRNA and plasmid 
DNA, through non-covalent cross-linking. Furthermore, 
calcium crosslinking of TAT (Ca-TAT) to siRNA or 
plasmid DNA condensed these complexes to nanoparticles, 
enhancing cellular transfection and gene knockdown more 
effectively, and with much lower toxicity than TAT CPPs 
alone or conventional polyethyleneimine particles [33-35].
Using Ca-TAT/siRNA complexes, we sought 
to evaluate the therapeutic efficacy of targeting gene 
expression of CCL2 in TNBC. Ca-TAT/siRNA complexes 
were observed to efficiently transfect MDA-MB-231 
and DCIS.com breast cancer cells plated in 2D and 3D 
cultures, and reduce CCL2 expression more effectively 
than CCL2 neutralizing antibodies. In contrast to CCL2 
antibody neutralization of breast tumor xenografts [21, 
22, 26], CCL2 gene silencing did not increase tumor cell 
apoptosis or affect tumor angiogenesis. Instead, CCL2 
gene silencing lead to increased tumor cell necrosis and 
autophagy, associated with a reduction in the number of 
cancer stem cells and recruitment of M2 macrophages. 
CCL2 gene silencing but not CCL2 antibody 
neutralization, significantly reduced CCL2 expression 
in breast cancer cells over time. Our studies are the first 
to demonstrate that targeting CCL2 expression exerts 
therapeutic effects different from blocking CCL2 activity 
through antibody binding. This study demonstrates a novel 
approach to target CCL2 and reveals important insight into 
the effects of CCL2 gene silencing on necrosis, autophagy, 
cancer stem cell renewal and macrophage recruitment.
RESULTS
Ca-TAT/siRNA particles target carcinoma cells 
to reduce CCL2 expression
We first characterized the efficiency of gene 
silencing from Ca-TAT/siRNA complexes using cell 
culture models. In previous studies, we demonstrated 
that CaCl2 concentration and N/P ratio were significant 
factors affecting transfection efficiency of cultured 
PyVmT mammary carcinoma cells [36]. Using a 
luciferase reporter assay, we had determined that N/P=5 
and 75 mM CaCl2 transfected mammary carcinoma cells 
most efficiently. Using this formula, Ca-TAT peptides 
were complexed to control eGFP siRNA, huCCL2si1 or 
huCCL2si2. According to ELISA analysis of 2D cultures, 
Ca-TAT delivery of huCCL2si1 or huCCL2si2 to either 
MDA-MB-231 or DCIS.com cells resulted in over a 50% 
knockdown in CCL2 expression, compared to Ca-TAT 
peptides complexed to control siRNA (Figure 1A-1B). 
We next determined the transfection efficiency of Ca-TAT/
siRNA complexes in 3D collagen cultures, which closely 
model the architecture of breast tumor tissues [37-39]. 
Ca-TAT delivery of huCCL2si1 or huCCL2si2 efficiently 
transfected MDA-MB-231 breast cancer cells embedded 
in collagen and silenced CCL2 expression at 24 and 48 
hours (Figure 1C). CCL2 neutralizing antibodies did 
not significantly affect CCL2 expression in 3D cultures 
(Figure 1D). In summary, these studies indicate that Ca-
TAT/siRNA complexes efficiently knock down CCL2 
expression in breast cancer cells.
Inhibition of tumor growth and invasion with 
CCL2 gene silencing
To recapitulate formation of TNBC with a 
humanized stroma, MDA-MB-231 cells were co-
transplanted with human carcinoma associated fibroblasts 
in collagen and transplanted in the inguinal mammary 
glands of nude mice [40, 41]. When tumors grew to 
approximately 0.5 cm in diameter, the xenografts received 
injections every three days with Ca-TAT complexed to 
control siRNA, huCCL2si1 or huCCL2si2, for a total of 
three injections per experimental group. Animals were 
sacrificed 30 days post-transplantation, when control 
tumors reached approximately 1.5 cm3 (Figure 2A), 
the maximum allowable tumor size, as outlined by the 
institutional animal care and use committee. CCL2 
expression levels in tumor tissues or surrounding normal 
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tissues were distinguished through flow cytometry 
staining with antibodies recognizing murine or human 
specific CCL2. Tumors receiving injections of Ca-TAT/
huCCL2si1 or Ca-TAT/huCCL2si2 showed a significant 
45% reduction in cells expressing overall human CCL2 
protein compared to tumors receiving injections of 
control siRNA. Silencing of CCL2 in tumor tissues 
down-regulated CCL2 protein expression to levels found 
in normal mammary tissues (Figure 2B). There were no 
significant differences in murine CCL2 protein expression 
with Ca-TAT delivery of control siRNA, huCCL2si1 or 
huCCL2si2, indicating that CCL2 expression in normal 
tissues were not affected by multiple injections of these 
complexes.
We determined the effects of CCL2 gene silencing on 
primary tumor growth and invasion. Compared to tumors 
treated with Ca-TAT/control siRNA complexes, tumors 
treated with Ca-TAT/huCCL2si1 exhibited a significant 
40% decrease in mass, while tumors treated with Ca-TAT/
huCCL2si2 exhibited a decrease in mass by 46% (Figure 
Figure 1: Ca-TAT peptides complexed to CCL2 siRNAs significantly reduce CCL2 protein expression in breast cancer 
cells. A. MDA-MB-231 or B. DCIS.com cells cultured in 2D were transfected with Ca-TAT peptides complexed to control (Con) or CCL2 
siRNAs (huCCL2si1 or huCCL2si2). 48 hours post transfection, conditioned media was measured by CCL2 ELISA. Par= Parental. C-D. 
MDA-MB-231cells were cultured in 3D collagen, and were transfected with Ca-TAT peptides complexed to siRNAs (C) or treated with 10 
μg/ml anti-CCL2 or IgG (D). CCL2 expression was measured in conditioned medium by ELISA, 24 hours and 48 hours post-treatment. 
Statistical analysis was performed by One way ANOVA followed by Bonferonni post-hoc analysis. Statistical significance was determined 
by p-value less than 0.05. *p<0.05, **p<0.01, n.s=not significant. Mean+SEM is shown.
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Figure 2: Ca-TAT delivery of CCL2 siRNAs inhibits growth and enhances cell death of primary MDA-MB-231 
tumor xenografts. A. Experimental plan for treatment of MDA-MB-231 tumor bearing mice with Ca-TAT/siRNA complexes. 21 days 
post transplantation, tumors received injections every three days with Ca-TAT peptides complexed to 10 micrograms control or CCL2 
siRNAs (huCCL2si1, huCCL2si2) for a total of three injections, n=6 per group. Animals were euthanized 30 days post-transplantation for 
tissue harvest and analysis. B. Tumor and surrounding normal mammary tissues were analyzed for CCL2 expression by flow cytometry 
C. Representative tumors with quantified tumor mass. D. Representative H&E stain of primary tumor xenografts. Necrotic areas were 
identified on H&E stains at 5 different depths of the tumor and quantified by Image J analysis. Necrotic areas are outlined. Scale bar= 200 
microns. Statistical analysis was performed by One way ANOVA followed by Bonferonni post-hoc comparisons with Control siRNA group. 
Statistical significance was determined by p-value less than 0.05. **p<0.01, ***p<0.001, n.s= not significant. Mean+SEM is shown.
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2C). By H&E stain, tumor tissues treated with complexes 
of Ca-TAT/huCCL2si1 or Ca-TAT/huCCL2si2 showed 
exhibited extensive necrotic cell death throughout the 
tumor, as indicated by loss of tumor cell membrane and 
nuclear integrity (Figure 2D). Tumor tissues were examined 
for changes in invasion into muscle tissue. By H&E stain 
and by co-immunofluorescence staining for Calsequestrin 
and Cytokeratin 5 (CK5), control treated tumors showed 
extensive invasion into muscle tissue (Figure 3A). Tumors 
treated with Ca-TAT/huCCL2si1 or Ca-TAT/huCCL2si2 
complexes showed a visible decrease in local invasion. In 
blinded studies, three different individuals scored tumor 
sections stained by H&E for invasion into muscle tissue. 
Sections at three different depths of the tumor were scored. 
Figure 3: CCL2 gene silencing inhibits primary and secondary invasion of MDA-MB-231 breast tumors. A. Top 
panels: Low magnification (4X) H&E stain with muscle tissue (M) and tumor tissue (T). Scale bar=1000 microns. Middle panels: Higher 
magnification (10x) H&E stain with muscle tissue and tumor tissue. Scale bar=400 microns. Bottom panels: CO-IF stain of Calsquestrin 
(green) and CK5 (red) in primary tumor xenografts. Overlays of Calsequestrin, CK5 and DAPI stain are shown. Scale bar= 400 microns. 
B. Metastatic lesions throughout the lung tissue were visually identified by hematoxylin staining as round shaped nodules using an inverted 
microscope and quantified. Representative images are shown. Metastatic nodules are outlined. Scale bar=80 microns. C. H&E stain of 
lung tissues. Metastatic lesions are circled. Scale bar=40 microns. Statistical analysis was performed by One way ANOVA followed by 
Bonferonni post-hoc comparisons with Control siRNA group (Con). Statistical significance was determined by p-value less than 0.05. 
**p<0.01. Mean+SEM is shown. N=6 animals per group.
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By statistical analysis, we observed that tumors treated 
with Ca-TAT/huCCL2si1 or Ca-TAT/huCCL2si2 has a 
significant number of lower scores than the control group 
(Table 1). When we analyzed for changes in metastasis, we 
observed a significant decrease in the number and size of 
lung metastases in mice treated with Ca-TAT/huCCL2si1 or 
Ca-TAT/huCCL2si2 complexes (Figure 3B-3C). These data 
indicate that Ca-TAT delivery of CCL2 siRNAs inhibits 
breast tumor growth, invasion and metastasis.
To further understand the effects of CCL2 silencing 
on tumor progression, primary breast tumor xenografts 
were examined for changes in cell proliferation and cell 
death by immunohistochemistry staining. We observed 
a significant reduction in PCNA expression from 42.9% 
with control siRNAs to 21.3% with huCCL2si1 and 21.2% 
with huCCL2si2. These data indicate decreased tumor 
cell proliferation (Figure 4A). No changes in cleaved 
caspase-3 expression were observed in the primary tumors 
among the experimental groups (Figure 4B). As tumor 
necrosis was observed by H&E stain, this phenotype was 
further confirmed by HMGB1 immunostaining. HMGB1 
expression was positive in viable tumor cell nuclei. Loss 
of HMGB1 expression was evident in cells that were 
absent of hematoxylin staining, indicating loss of intact 
nuclei. Compared to Ca-TAT/control siRNA treatment, 
Ca-TAT delivery of either CCL2 siRNAs reduced HMGB1 
in the primary tumor by over 75% (Figure 4C), further 
demonstrating increased necrosis in the primary tumor 
with CCL2 gene silencing. To identify for possible changes 
in cellular autophagy, tumors were immunostained for 
LC3B expression. Compared to Ca-TAT/control siRNA 
treatment, Ca-TAT delivery of huCCL2si1 or huCCL2si2 
increased LC3B expression by over 45% (Figure 4D). 
Taken together, silencing of CCL2 gene expression results 
in decreased breast tumor cell proliferation, and increased 
necrosis and autophagy.
Ca-TAT/siRNA complexes inhibits the growth of 
tumor initiating cells
Tumor initiating cells (also referred to as cancer stem 
cells or CSCs) contribute to breast cancer recurrence and 
development of metastatic breast cancer [42]. CSCs resist 
uptake of conventional chemotherapeutic drugs through a 
number of mechanisms, including increasing expression of 
ALDH1 [43, 44]. Thus, ALDH1 is considered a marker for 
cancer stem cells. Recent studies have shown that CCL2 
enhances cancer stem cell renewal of some luminal breast 
cancer cell lines in vitro [45]. However, the relevance of 
CCL2 expression to cancer stem cell renewal in TNBC is 
unclear. Therefore, we first determined the effect of CCL2 
gene silencing on the numbers of CD24-/CD44+ cells, 
a well characterized breast cancer stem cell population 
[46]. By FACs analysis, Ca-TAT delivery of huCCL2si1 
or huCCL2si2 decreased the numbers of CD24-/CD44+ 
cells by over 50% (Figure 5A). By immunohistochemistry 
analysis of MDA-MB-231 breast tumor xenografts, we 
observed a significant reduction in ALDH1 expression in 
CCL2 deficient tumors (Figure 5B). These data indicate 
that CCL2 knockdown inhibits ALDH1 expression 
and numbers of CD24-/CD44+ cells in breast tumor 
xenografts.
We also examined that the effects of CCL2 
gene silencing on mammosphere formation in vitro. 










Individual 1 Control 5 8 5 0.04
huCCL2si1 12 6 0
huCCL2si2 11 7 0
Individual 2 Control 0 7 11 0.0001
huCCL2si1 12 4 2
huCCL2si2 11 2 3
Individual 3 Control 1 7 10 0.01
huCCL2si1 9 6 3
huCCL2si2 5 9 4
Three serial tumor sections at three different depths, 50 microns apart were scored in a blinded fashion by three different 
individuals using a numerical scoring system. 0= No to little invasion. 1= some invasion, 2= high invasion. The scores for 
each depth were averaged per sample, resulting in 3 scores per sample, and with n=6 tumor samples per group, this resulted 
in a total 18 scores per group. Statistical analysis was determined by Chi Square test. Statistical analysis was determined by 
p<0.05. Analyses by individuals are shown.
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The mammosphere assay, developed by Dontu et al 
[47] involves culturing of breast epithelial cells under 
low attachment conditions, which form spheroids in 
suspension. When these mammospheres were diassociated, 
these cells grew into new spheroids, which could be 
measured as an indicator of self–renewal. Dontu et al 
showed that mammospheres included a mix of progenitor 
and stem cells. When plated onto a 2D substrate, these 
spheroids differentiated into ductal and myoepithelial cells 
[47]. When we cultured MDA-MB-231 cells under low 
attachment conditions, these cells formed asymmetrical 
cellular aggregates or “mammospheres,” which could 
be passaged a minimum of four times, consistent 
with previous studies [48, 49]. Mammospheres were 
transfected with Ca-TAT peptides complexed to control 
or CCL2siRNAs once every passage for up to 4 passages. 
Compared to the control siRNA treated group, huCCL2si1 
or huCCL2si2 significantly decreased the numbers of 
cellular aggregates formed by MDA-MB-231 breast 
cancer cells (Figure 5C). Consistently, Ca-TAT delivery 
of huCCL2si1 and huCCL2si2 resulted in fewer numbers 
of DCIS.com mammospheres at passage 4 (Supplementary 
Figure 1). Taken together, these data indicate that CCL2 
gene silencing inhibits self-renewal of MDA-MB-231and 
DCIS.com breast cancer cells.
Figure 4: CCL2 gene silencing enhances necrosis and autophagy in MDA-MB-231 breast tumor xenografts. MDA-
MB-231 breast tumor xenografts were injected with Ca-TAT peptides complexed to control siRNAs (Con), or CCL2 siRNAs (huCCL2si1 
or huCCL2si2), and immunostained for expression of A. PCNA, B. Cleaved caspase-3, C. HMGB1, or D. LC3B. Scale=100 microns. 
Statistical analysis was performed by One Way ANOVA followed by Bonferonni post-hoc analysis. Statistical significance was determined 
by p-value less than 0.05. *p<0.05, ***p<0.001, n.s=not significant. Mean+SEM is shown. N=6 animals per group.
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Ca-TAT delivery of CCL2 siRNAs inhibit 
macrophage recruitment in MDA-MB-231 
breast tumor xenografts
To investigate the mechanisms contributing to the 
decreased growth and invasion of CCL2 deficient tumors, 
we examined the possibility that reduced bioavailability 
of CCL2 protein would inhibit stromal reactivity in the 
primary tumor. CCL2 promotes angiogenesis [50] and 
macrophage recruitment [21-23] to primary tumors. 
Ca-TAT delivery of huCCL2si1 or huCCL2si2 lead to 
over a 50% reduction in CD11b+ cells in primary tumor 
xenografts, as determined by flow cytometry (Figure 
6A). Imunohistochemistry analysis revealed increased 
expression of Arginase I expressing cells localized to 
necrotic areas in control tumors, indicating the presence of 
M2 macrophages [51, 52]. CCL2 knockdown significantly 
reduced the number of M2 macrophages localized to 
necrotic tissues (Figure 6B). CCL2 deficient tumors 
did not show significant differences in expression of 
Von Willibrand Factor 8, a blood vessel marker (Figure 
6C). In summary, CCL2 gene silencing decreases M2 
macrophage recruitment in TNBC xenografts, and does 
not significantly affect tumor angiogenesis.
Figure 5: CCL2 gene silencing in breast cancer cells by Ca-TAT/siRNA complexes inhibits cancer stem cell renewal. 
A-B. MDA-MB-231 breast tumor xenografts (N=6 animals per group) were treated with control (Con) or Ca-TAT complexed to CCL2 
siRNAs (huCCL2si1, huCCL2si2), and were analyzed for CD24 and CD44 expression by flow cytometry (A), or ALDH1 expression by 
immunohistochemistry stain (B). ALDH1 expression was quantified by Image J; arbitrary units are shown. Scale bar=100 microns. C. MDA-
MB-231 cells in culture were transfected with Ca-TAT/siRNA complexes and examined for mammosphere formation. Representative images 
are shown at passage 4. Scale bar=200 microns. Statistical analysis was performed by One Way ANOVA followed by Bonferonni post-hoc 
comparisons with Control group. Statistical significance was determined by p-value less than 0.05. *p<0.05, **p<0.01. Mean+SEM is shown.
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Previous studies have shown that macrophages 
express CCL2, and have suggested that CCL2 regulates 
macrophage recruitment to primary breast tumors 
through a positive feedback loop [22]. To determine the 
contribution of epithelial specific CCL2 to macrophage 
recruitment, we used a novel in vitro macrophage 
infiltration assay using a 3D cell culture fluidics device 
developed in our laboratory, termed the Metastatic 
Mimetic Device (MMD) [53]. The MMD consists of 
dual chambers with openings, which fit into one another, 
and swivels to create a closed system (Figure 7A). The 
closed system allows for the culture of cells in matrix 
inside the chamber. Alignment of the chamber openings 
permits migration of immune cells into the chamber such 
as macrophages. To determine the contribution of tumoral 
CCL2 to macrophage recruitment, MDA-MB-231 breast 
cancer cells were embedded in 3D collagen in the MMD. 
Ca-TAT/siRNA complexes were transfected into the 3D 
cultures. Raw 264.7 mcherry cells were plated outside the 
device, and analyzed for migration into the MMD at 24 and 
48 hours (Figure 7B). MDA-MB-231 breast cancer cells 
embedded in collagen significantly enhanced migration 
of Raw 264.7 macrophages into the MMD compared to 
collagen alone, indicating that macrophage infiltration 
into the MMD was specific to breast cancer cells (Figure 
7C). CCL2 knockdown in MDA-MB-231 or DCIS.com 
cells significantly inhibited the numbers of macrophages 
migrating into the MMD (Figure 7D, Supplementary 
Figure 2). These data indicate that epithelial expression of 
CCL2 is important for regulating macrophage recruitment.
IL-6 and VEGF are two key factors overexpressed 
in breast tumors [54-56]. VEGF and IL-6 both regulate 
Figure 6: CCL2 gene silencing in MDA-MB-231 breast tumor xenografts inhibits M2 macrophage recruitment but 
not tumor angiogenesis. MDA-MB-231 breast tumor xenografts were examined for A. CD11b expression by flow cytometry, B. 
Arginase I, or C. Von Willebrand Factor 8 (VWF8) expression, by immunohistochemistry. Scale bar=100 microns. Expression levels were 
quantified by Image J; arbitrary units are shown. Statistical analysis was performed by One Way ANOVA followed by Bonferonni post-hoc 
comparisons with Control group. Statistical significance was determined by p-value less than 0.05. *p<0.05, **p<0.01, n.s= not significant. 
Mean+SEM is shown. N=6 animals per group
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tumor angiogenesis [57, 58]. IL-6 is also associated 
with recruitment of myeloid cells and increased cancer 
cell growth and migration [56, 59, 60]. CCL2 has 
been shown to regulate expression of IL-6 expression 
in lung fibroblasts [61] and VEGF in melanoma cells 
[62]. In addition, studies have shown that treatment of 
breast tumor xenografts with neutralizing antibodies 
to CCL2 lead to increased expression of IL-6 and 
VEGF when anti-CCL2 treatment was interrupted 
[26]. These studies indicate a functional association 
between CCL2 expression and VEGF and IL-6. We 
examined expression of VEGF and IL-6 through 
immunostaining of MDA-MB-231 tumor xenografts, 
and did not detect any significant changes in VEGF or 
IL-6 expression (Supplementary Figure 3A). MDA-
MB-231 breast cancer cells transfected with Ca-TAT 
peptides complexed to CCL2 siRNAs did not show 
any significant changes in VEGF or IL-6 expression in 
conditioned medium by ELISA (Supplementary Figure 
3B). These data indicate that CCL2 siRNAs do not 
significantly affect expression of VEGF or IL-6.
Figure 7: CCL2 gene silencing inhibits macrophage recruitment to MDA-MB-231 breast cancer 3D cultures. A. Diagram 
of MMD function. Dual wall design allows user to control size of flow-through opening by twisting the inner and outer chambers in and 
out of alignment. B. Experimental design: MDA-MB-231 breast cancer cells were embedded in collagen within the MMDs, which were 
placed in 6 well dishes. mCherry labeled Raw264.7 macrophages were plated outside the devices, and assayed for migration into the MMD 
over 24-48 hours. C. Representative images of Raw 264.7 mcherry macrophage infiltration into collagen alone or collagen embedded with 
breast cancer cells after 48 hours. Fluorescence images overlayed with phase contrast images are shown. Scale bar=100 microns. Arrow 
points to unlabeled MDA-MB-231 breast cancer cells. D. MDA-MB-231 cells were cultured in 3D collagen in the MMDs, transfected 
with Ca-TAT/siRNA complexes, and analyzed for macrophage infiltration into the MMD. Macrophage infiltration was quantified by Image 
J; arbitrary units shown. Statistical analysis was performed by One way ANOVA followed by Bonferonni post-hoc analysis. Statistical 
significance was determined by p-value less than 0.05. *p<0.05, **p<0.01, ***p<0.0001, n.s=not sigificant. Mean+SEM is shown.
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DISCUSSION
The value of CCL2 as a therapeutic target is 
controversial. Through a novel gene silencing approach, 
we show that targeting CCL2 expression inhibits tumor 
progression associated with a reduction in cancer stem 
cells and M2 macrophages. Previous studies have mainly 
used neutralizing antibodies to evaluate the role of CCL2 
in tumor progression. However, this approach does not 
affect CCL2 expression. Our studies indicate that targeting 
CCL2 expression may provide significant therapeutic 
effects to treat TNBC.
For the first time, we provide proof of concept data 
that Ca-TAT/siRNA complexes are capable of penetrating 
breast tumors and inducing gene silencing. Currently, 
systemic delivery remains the most commonly used 
method for distributing drugs to primary and secondary 
tumor tissues, but is highly inefficient, frequently leading 
to insufficient drug penetration into tissues [63, 64]. 
These studies underscore a need to identify alternative 
treatment strategies to enhance both specificity and 
efficacy of treatment. Localized delivery of drugs to 
human cancer patients have long been considered a 
selective and potentially more effective approach for 
enhancing drug efficacy [65, 66]. In our studies, we show 
that local delivery of CCL2 siRNAs through Ca-TAT 
peptide complexes lead to efficient and sustained CCL2 
knockdown in tumor cells, without adversely affecting 
viability or gene expression in surrounding normal 
mammary tissue. Localized delivery of Ca-TAT/siRNA 
complexes to tissues with metastatic lesions could also 
be effective in therapeutic intervention. Recent studies 
demonstrated that intra-tracheal delivery of Ca-TAT/
pDNA complexes penetrated primary lung cancer [67]. 
This approach could be used to treat breast cancer patients 
with existing lung metastases. Further studies must be 
performed to evaluate the efficacy, pharmacokinetics, 
and long-term safety of different delivery approaches of 
Ca-TAT/siRNA complexes for therapeutic intervention of 
distant metastasis.
One possible concern with local injection is the 
ability of the Ca-TAT/siRNA complexes to reach their 
target site before dissociation, due to the weak calcium 
ionic interactions. A major factor affecting disassociation 
of the Ca-TAT complexes is pH. Studies of Ca-TAT 
complexes in the cytosol indicate that low pH may 
mediate disassociation of the Ca-TAT complexes [68, 69]. 
At pH 7.4, the particle size of the complexes was shown 
to be approximately 250 nm irrespective of the CPP used 
[68]. Particle size increased when the pH was lowered 
to 4.4, suggesting that an acidic environment reverses 
the condensing effect of calcium. This pH-induced 
dissociation was previously reported for DNA/calcium 
complexes [69, 70]. At the neutral pH, the zeta potential 
values were positive, indicating that the positively charged 
CPPs form the bulk of the condensed gene complexes. 
The net charge on the particles was switched when 
the pH was lowered, and the gene complexes became 
anionic or neutral. These data indicate that lowering 
the environmental pH destabilized the non-covalently 
condensed pDNA complexes, allowing the pDNA to 
be exposed or released from the complex [68]. This 
hypothesis is further supported by other studies of calcium 
and DNA precipitates, which were shown to dissociate 
when exposed to similar conditions [70, 71]. The pH 
in the extracellular space is approximately 7.4 under 
normal conditions and 7.1 in tumor tissues [72]. Despite 
the lower pH in the extracellular space of tumor tissues, 
previous studies showed that Ca-K9 peptide/pDNA 
complexes significantly attenuated lung tumor growth 
macroscopically and microscopically when delivered 
by tail vein injection [68]. These studies indicated that 
calcium condensed peptide/pDNA complexes were 
capable of traveling from the tail to the lung before 
disassociating within the lung tumor cells. Further studies 
must be performed to more precisely measure the radius 
from the injection site at disassociation might occur.
CCL2 antibody neutralization inhibited tumor 
progression in mice bearing 4T1 or MDA-MB-231 breast 
tumor xenografts [21, 22]. When anti-CCL2 treatment was 
stopped midway and 4T1 tumors were surgically removed, 
the anti-CCL2 treated mice showed increased metastasis 
associated with increased expression of IL-6 and VEGF, 
compared to control IgG treated mice. From these data, 
the authors suggested that cessation of CCL2 inhibition 
may accelerate metastasis by enhancing expression of 
pro-angiogenic factors [26]. However, it was unclear 
from that study whether CCL2 antibody neutralization 
had any significant effects on CCL2 expression levels 
in the tumors. A phase I clinical trial study on CCL2 
antibody neutralization in rheumatoid arthritis patients 
showed that antibody bound CCL2 complexes were still 
biologically active and that CCL2 levels were increased 
in patients [25]. Therefore, it is possible that anti-CCL2 
treatment could sequester CCL2 temporarily, but not 
prevent long-term clearance of CCL2. As a result, CCL2 
levels would accumulate once the antibody itself became 
inactive. In our study, we showed that siRNA delivery 
effectively reduced CCL2 expression in the primary 
tumors to levels normally found in normal mammary 
tissues, and suppressed tumor progression. However, we 
did not observe any significant changes in VEGF or IL-6 
expression in MDA-MB-231 breast tumor xenografts 
or cells. It is likely that multiple mechanisms regulate 
expression of these factors. For example, IL-1 and TGF-β 
are expressed in breast cancer [73], and regulate VEGF 
and IL-6 expression [74-77]. In summary, our data suggest 
that directly targeting CCL2 expression would be a more 
effective means to inhibiting CCL2 biological activity in 
vivo, compared to antibody neutralization. Furthermore, it 
may not be necessary to eliminate CCL2 expression levels 
from the tumor to inhibit tumor progression.
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In our studies, we found that CCL2 knockdown 
increased expression of LC3B, indicating cellular 
autophagy. Autophagy has been associated with cancer cell 
survival as a means to conserve energy when experiencing 
metabolic stress [78, 79]. Knockdown of autophagy 
related genes ATG7 or Beclin1 enhanced necrotic cell 
death in fibrosarcoma cells [80], indicating that autophagy 
protects against necrotic cell death. On the other hand, 
autophagy may also be important for promoting cell death. 
Autophagic cell death was observed with treatment of 
ovarian cancer cells with platinum or pituitary cancer cells 
with cyclosporine [81]. Knockdown of ATG-7 or Beclin1 
inhibited necrosis in Caenorhabditis elegans [82]. In our 
studies, it is possible that the increased autophagy in our 
studies represented a pro-survival mechanism as a reaction 
to CCL2 knockdown, or functioned to promote cell death. 
To further characterize the role and mechanisms of 
autophagy in CCL2 signaling in breast cancer, extensive 
studies on the autophagy pathway and cell death would 
be necessary. These studies are beyond the scope of this 
report, but are of interest in the future.
Our data indicate that CCL2 gene silencing 
significantly remodeled the microenvironment to suppress 
tumor progression. In tumors treated with Ca-TAT/control 
siRNA complexes, central necrosis was surrounded 
by a large peripheral zone of proliferating tumor cells. 
Furthermore M2 macrophages were localized to the 
necrotic areas. These phenotypes in the control tumors 
are consistent with previous studies showing that tumors 
may potentially exploit hypoxia induced by necrosis to 
upregulate angiogenesis and recruit M2 macrophages [83-
86]. CCL2 knockdown increased necrosis in the primary 
tumor. Fewer macrophages were observed in necrotic 
tissues, and no significant changes in angiogenesis were 
detected. These studies indicate that decreased CCL2 
levels in the primary tumor inhibit the ability of invasive 
breast tumors to exploit the surrounding host cells. In 
contrast, antibody neutralization of CCL2 in tumor 
xenografts enhanced tumor cell apoptosis [21-23]. CCL2 
gene silencing may provide a more selective therapeutic 
advantage in cases where tumors are resistant to apoptosis 
[87, 88].
Targeting cancer stem cells represents a promising 
strategy for therapeutic intervention of recurrent or 
metastatic breast cancers, which often develop resistance 
to conventional chemotherapeutics [42, 44]. In vitro 
studies have shown that commonly used therapeutic drugs, 
such as paclitaxel, selects for survival of breast cancer stem 
cell populations, possibly contributing to tumor recurrence 
over time [89, 90]. Cancer stem cells resist the effects of 
chemotherapeutic drugs through a number of mechanisms 
including: drug efflux through transporter proteins, pro-
survival signaling, increased ALDH1 expression and 
quiescence [43, 44]. In our studies, we demonstrated that 
CCL2 gene silencing in MDA-MB-231 tumor xenografts 
inhibited ALDH1 expression, and reduced the number of 
CD24-/CD44+ cells. One likely mechanism is that Ca-
TAT/siRNA complexes directly inhibited the growth of 
CSCs, as indicated by mammosphere assays. Through 
an indirect mechanism, the reduction in macrophages 
in CCL2 deficient tumors may have also affected CSC 
renewal, as M2 macrophages express soluble factors that 
promote cancer stem cell renewal, tumor growth and 
invasion [91-93]. Thus, CCL2 gene silencing via TAT/
siRNA complexes inhibit key mechanisms that promote 
progression of TNBC.
In summary, CCL2 knockdown through delivery 
of Ca-TAT/siRNA complexes could be an effective 
treatment strategy for the treatment of invasive breast 
cancer, particularly when combined with other anti-
cancer therapies. Combined with previous studies, our 
studies indicate that Ca-TAT/siRNA complexes selectively 
penetrate tumor tissues. TAT peptides are already being 
tested in the clinic for the treatment of heart disease [94]. 
Translating Ca-TAT/siRNA complexes as an anti-cancer 
strategy in the clinic is highly feasible. This low toxicity, 
high versatility approach supports translation of Ca-TAT/
siRNA complexes to the clinic for the treatment of cancer.
MATERIALS AND METHODS
Cell culture
MDA-MB-231 cells were obtained from American 
Tissue Culture Collection. Cancer associated fibroblasts 
were isolated from invasive breast ductal carcinoma 
and characterized in previous studies [95, 96]. DCIS.
com cells were generously provided by Fariba Behbod, 
PharmD, Ph.D (University of Kansas Medical Center). 
Raw 264.7 mcherry cells were generously provided by 
George Veilhauer, Ph.D (University of Kansas Medical 
Center, Kansas City, KS). All cell lines were cultured on 
plastic in DMEM media containing 10% FBS with 0.1% 
amphotericin, 1% penicillin-streptomycin (cat no. 30-004-
CI, Cellgro).
siRNA/plasmid reagents
Sense and anti-sense oligonucleotides were 
synthesized and annealed by GE Dharmacon. The 
following siRNA targeting sequences were designed: 




Preparation of Ca-TAT complexes
The following formula was used to determine the 
amount of TAT peptide needed for a specific N/P ratio per 
μg of DNA or siRNA: μg of TAT = 0.446 *(N/P ratio) 
+ 0.116. For example, complexing 2.346 μg of TAT per 
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1 μg of DNA or siRNA would yield N/P=5. To prepare 
complexes, TAT peptides were mixed with siRNA or 
pDNA in 45 μl sterile deionized water containing: 37.5 
mM, 75 mM or 112.5 mM CaCl2. The solution was 
pipetted vigorously for 20 times and incubated on ice 
for 20 minutes. For 2D and 3D cell culture studies and 
mammosphere assays, cells were incubated directly with 
the complexes for 24 hours before media replacement. For 
in vivo studies, 25 μl of 10 % glucose was added to the 
complexes, and diluted with PBS to a total volume of 100 
μl before use.
3D cell culture
In each well of a 24 well plate, 100,000 breast 
cancer cells were embedded in 200 μl rat tail collagen 
(BD Pharmingen) using methods adapted from previous 
studies [98]. Briefly, the pH of 2 mg/ml of stock collagen 
was adjusted by mixing at a 4:1 ratio with setting solution 
comprised of: 1X EBSS, 75 mM NaOH, and 290 mM 
NaHCO3. Breast cancer cells were detached from the plate 
by trypnization, quenched, counted by hemocytometer, 
and pelleted by centrifugation. 100,000 cells were mixed 
thoroughly with 250 μL collagen solution and pipetted 
directly in each well, and incubated at 37C for 30 minutes 
for polymerization of collagen. Cells were incubated in 1 
ml of DMEM/10% FBS for 24 hours prior to transfection.
ELISA
For each well in a 24 well plate, 40,000 cells were 
seeded in a monolayer or 100,000 cells were seeded in 
collagen for 24 hours in DMEM/10% FBS. To generate 
conditioned medium, cells were washed in PBS and 
incubated in serum free DMEM for 24 hours in 500 μl 
volume per well. Conditioned media generated from 
indicated cell lines were subject to ELISA specific to 
human CCL2 (cat no.900-M31, Peprotech), VEGF 
(cat no. 900-K10, Peprotech) or IL-6 (cat no. 900-
K16, Peprotech). Samples were analyzed according to 
manufacturer protocol. Reactions were catalyzed using 
tetramethylbenzidine substrate (cat no. 34028, Pierce) 
according to manufacturer’s instructions. Absorbance was 
read at OD 450 nM using a BioTek Microplate Reader.
Animal care and surgery
Female athymic Foxn1nu/nu mice, 6-8 weeks old 
(Balb/c background) were purchased from Envigo, Inc. 
Animals were maintained at the University of Kansas 
Medical Center, in accordance with the Association for 
Assessment and Accreditation of Laboratory Animal Care 
(AALAC). All animal experiments were performed at the 
University of Kansas Medical Center under an approved 
IACUC. 250,000 human carcinoma associated fibroblasts 
were embedded with 100,000 MDA-MB-231 cells in 50 
μl of collagen rat tail collagen I (BD Pharmingen), using 
methods previously described [40]. One collagen plugs 
was transplanted into each mouse, in the #4-5 inguinal 
mammary glands. When the tumors reached 0.5 cm in 
diameter, 10 μg (100 μl) of Ca-TAT/control or Ca-TAT/
CCL2 siRNA nanoparticles were injected into the primary 
tumor in 4 different areas of the tumor, using a 27 gauge 
needle. Each mouse received a total of 3 injections of 
Ca-TAT/siRNA complexes. Animals were monitored 
twice weekly for tumor formation by palpation and 
measurement by caliper. Animals were euthanized 30 
days post-transplantation, when control tumors reached 
maximum allowable tumor size, approximately 1.5 cm3 
(Figure 2A).
Tissue embedding
Tissues were fixed in 10 % neutral formalin buffer 
for 24 hours. Tissues were embedded in wax as described 
[98]. Briefly, tissues were dehydrated in a series of 
alcohols: 70, 90, 100% ethanols for 1 hour each. Tissues 
were further dehydrated in isopropanol for 1 hour, 50:50 
ratio of isopropanol: paraffin wax at 60°C for 1 hour and 
then in wax at 60°C overnight. Tissues were placed into 
the wax containing molds and allowed to harden at room 




Wax embedded sections were sectioned at 5 
micron thickness onto 1 mm glass slides, dewaxed and 
rehydrated as described [98]. For H&E stain, slides were 
incubated in Harris’s hematoxylin for 2 minutes and 
eosin for 2 minutes prior to dehydration and mounting 
in Cytoseal. For immunostaining, tissue sections were 
subjected to antigen retrieval through heating in low 
pressure in sodium citrate buffer pH 6.0 for 2 minutes. 
Slides were washed in PBS, and endogenous peroxidases 
were quenched in PBS containing 60 % methanol and 
3% H2O2. Samples were blocked in PBS containing 3% 
fetal bovine serum for 1 hour, and incubated with primary 
antibodies (1:100) to: cleaved caspase-3 Asp 175 (cat no. 
9579, Cell Signaling Technology), HMGB1 (cat no.6393, 
Cell Signaling Technology), LC3B (cat no. L10382, 
Life Technologies), VWF8 (cat no. Ab7356, Millipore), 
arginase I (cat no. sc20150, Santa Cruz Biotechnology) 
or VEGF (cat no. sc-152, Santa Cruz Biotechnology) 
overnight at 4°C. Slides were washed in PBS three times, 
incubated with secondary rabbit biotinylated antibodies 
at 1:1000 dilution (cat no. BA-5000, Vector Labs) for 2 
hours, conjugated with streptavidin peroxidase (cat no. 
PK-4000, Vector Labs) and incubated with DAB substrate 
(cat no. K346711, Dako). For detection of PCNA or IL-6 
endogenous mouse immunoglobulins were first incubating 
with blocking reagents from the Mouse on Mouse kit 
(cat no. BMK-2202, Vector Laboratories), according to 
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commercial protocol. Slides were incubated with PCNA 
antibodies (cat no. sc25280, Santa Cruz Biotechnology) or 
IL-6 antibodies (cat no. MAB-2061m RnD Systems) at a 
1:100 for 1 hour and then incubated with secondary mouse 
biotinylated antibodies from the MOM kit at a 1:250 
dilution for 1 hour. For detection of CD24, slides were 
incubated with antibodies at a 1:100 (cat no. 561777 BD 
Pharmingen), and detected with secondary rat-biotinylated 
antibodies (cat no.BA-9401, Vector Laboratories) at 
a 1:1000 dilution. Sections were counterstained with 
Harris’ hematoxylin for 1 minute, dehydrated and mounted 
with Cytoseal. Because tumor sections were of various 
sizes, it was determined that 4 fields could be captured 
consistently among tumor samples, while enabling a good 
representation of the tumor. Therefore, four random fields 
per section, with 2 sections per sample, were captured 
at 10 x magnification using a Motic AE 31 microscope 
with Infinity2-1c color digital camera. DAB staining was 
quantified by pixel density analysis, normalized to total 
tumor area, using an Image J software protocol (NIH) 
described in previous studies [98-101].
For immunofluorescence, sections were incubated at 
1:100 dilution of antibodies to Cytokeratin 5 (CK5, cat no. 
XM-26, ThermoFisher ) and Calsequestrin (cat no. SC-
28274, Santa Cruz Biotechnologies overnight at at 4°C, 
conjugated with anti-rabbit-Alexa-568 and anti-mouse-
Alexa-488 at a 1:500 dilution for 2 hours. Sections were 
washed in PBS, counterstained with DAPI and mounted 
with PBS/glycerol.
Quantification of tumor necrosis
To quantify the extent of necrosis in breast tumor 
xenografts, tumor tissues were sectioned at 5 different 
depths, approximately 50 microns apart. 3 sections from 
each depth were placed on a slide and stained by H&E. 
Sections were imaged at 4x magnification, at 2-3 fields 
per section to capture the whole tissue section. Software 
analysis for necrotic areas in breast tissues was performed 
using methods adapted from previous studies [96]. Images 
were first imported into Adobe Photoshop. Color and 
exposure of images were normalized using auto-contrast. 
Necrotic areas were selected using a lasso tool, copied 
to a new window and saved a separate file. Images were 
opened in Image J software (NIH), and converted to grey 
scale. Background pixels resulting from luminosity of 
brightfield images were removed by threshold adjustment. 
Images were the subject to particle analysis. Necrotic 
areas and total areas were expressed as particle area values 
of arbitrary units. Values representing necrotic areas were 
normalized to values representing total tissue section.
Scoring of tumor invasion
To quantify the extent of tumor invasion into muscle 
tissue, tumor tissues were sectioned at 3 different depths 
approximately 50 microns apart. Three serial sections 
from each depth were placed on each slide and stained by 
H&E. The muscle tissue was distinguished by a striated 
appearance that was strongly positive for eosin stain. 
Each section from each sample was scored for extent of 
invasion by analysis of slides at 4x and 10x magnification. 
Three different individuals in blinded studies used a 
numerical scoring system. 0 indicated no to low invasion, 
characterized by no or a few tumor viable cells present in 
muscle tissue, or the presence of necrotic tumor cells in 
muscle tissue; the border between muscle and tumor tissue 
was well defined. 1 indicated some tumor cell invasion, 
characterized by viable tumor cells present in muscle 
tissue; the border between muscle and tumor tissue was 
less defined. 2 indicated high invasion characterized by 
extensive number of tumor cells in muscle tissue; tumor 
was embedded in muscle, and the border between muscle 
tissue and tumor undefined.
Quantitation of lung metastases
Metastatic nodules in lung tissues were detected and 
quantified using hematoxylin staining approach of lung 
tissues, as previously described in previous studies [99]. 
Briefly, tissues were dehydrated a series of alcohols: 70, 
90, 100% ethanols for 1 hour each and cleared in xylene 
overnight. Tissues were rehydrated in decreasing series of 
ethanols, flushed with running tap water for 15 minutes 
and then stained with Gill’s hematoxylin for 10 minutes. 
Lung tissues were flushed with water for 5 minutes, de-
stained in 1 % HCl for 20 minutes, and then incubated 
in tap water overnight. Tissues were partially dehydrated 
in 70% ethanol for 1 hour. Metastatic lesions throughout 
the lung tissue were visually identified by hematoxylin 
staining as round shaped nodules under brightfield/
phase contrast microscopy using a Motic AE31 inverted 
microscope (Motic AE31). Metastatic nodules were 
manually scored in the lung tissues. The presence of 
metastases was confirmed by paraffin embedding of whole 
tissue, and H&E stain of lung sections.
Flow cytometry
For adherent cells in culture, cells were first 
detached from plastic by washing in PBS twice, and 
incubation in 3 mM EDTA at 37°C for 10-15 minutes. 
Cells were washed with 10 ml of complete medium twice, 
fixed in 10 % neutral formalin buffer for 10 minutes at 
room temperature and washed with PBS twice to remove 
traces of formalin. For tumor tissues, tissues were washed 
in PBS, and digested into single cell suspensions with 
collagenase I and trypsin for 4 hours at 37°C, as described 
in previous studies [21, 102-104]. Tumor cell suspensions 
were fixed in 10% NBF for overnight at 4C, and then 
washed with PBS twice to remove traces of formalin. 
Cells were permeabilized with 0.1 % Triton-X 100 in a 
37°C water bath for 15 minutes, and washed in PBS twice. 
Samples were incubated with the following antibodies at 1: 
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50 dilution, overnight on ice in PBS containing 2% BSA: 
CD24- PE (cat no.555428, BD Pharmingen), CD11b-APC-
Cy7 (cat. no 557657, BD Pharmingen), murine CCL2 
(cat no. 1784, Santa Cruz Biotechnology), human CCL2 
(cat no. sc1304, Santa Cruz Biotechnology) Ki67 (cat 
no. Sc15402, Santa Cruz Biotechnology), HMGB1 (cat 
no. 6893, Cell Signaling Technology) or LC3B (cat no. 
L10382, Invitrogen). Samples were incubated with anti-
Fsp1 at a dilution of 1:3 (cat no. ab75550, Abcam). Murine 
CCL2 and human CCL2 were detected by secondary goat 
antibodies conjugated to Alexa-488 (1:500) in PBS for 1 
hour on ice, covered in foil. Fsp1, Ki67, HMGB1, LC3B 
were detected by secondary rabbit antibodies conjugated 
to Alexa-647 at a 1:500 dilution on ice for 1 hour. Cells 
were washed with PBS three times prior to analysis. 
Samples were analyzed on a LSRII Flow cytometer, 
normalized to secondary antibody only controls.
Mammosphere assay
30,000 cells were seeded in low attachment 6 
well plates (Corning) in 3 ml of DMEM/10% FBS. 
48 hours after plating, cells were transfected with Ca-
TAT complexed to 3 ug of control, huCCL2si1 or 
huCCLsi2 siRNAs. After an additional 5 days in culture, 
mammospheres were collected in 15 ml conical tubes, 
pelleted, and disassociated using 20 mM Trypsin/2 mm 
EDTA solution for 7 minutes at 37C. Cells were pelleted 
and replated for 48 hours before re-transfection with Ca-
TAT/siRNA complexes. Images were captured using the 
EVOS FL auto every 7 days of plating. Mammospheres 
were counted using Image J software.
3D macrophage infiltration assay
MMD fluidic devices were fabricated by 
MetaBioscience LLC (Overland Park, KS). For each 
chamber device, 100,000 breast cancer cells were 
embedded in 250 μl rat tail collagen (BD Pharmingen), as 
described for 3D cultures. Devices were placed in 6 well 
dishes. 1 ml of DMEM/10% FBS was pipetted into the 
device and incubated overnight. After overnight incubation 
of the devices, 500,000 Raw 264.7 mcherry cells were 
counted and re-suspended into 2.5 ml of DMEM/10% 
FBS for each device. Devices were twisted open and 
cells were pipetted into each well, outside of the device. 
Devices were imaged daily at 10x magnification using an 
EVOS FL auto imaging system (Invitrogen) for up to 48 
hours. The number of macrophages were measured by 
quantification of fluorescence using methods previously 
described [98].
Statistical analysis
All experiments were repeated a minimum of three 
times. Data are expressed as mean+ standard error of the 
mean (SEM) Statistical analysis was determined using 
Two-Tailed T-test or ANOVA with Bonferonni’s post-hoc 
comparisons using Graphpad Software. Significance was 
determined by p<0.05. *p<0.05, **p<0.01, ***p<0.0001, 
n.s=not significant or p>0.05.
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